Latest Leadership News

SenSen Networks has reported a strong financial turnaround in FY2025, driven by rapid expansion in North America and innovative AI kerb enforcement technology. The company’s improved margins and positive cash flow signal a promising outlook for its Smart Cities strategy.

Aerometrex reported a mixed FY25 with strong MetroMap subscription growth boosting EBITDA despite a decline in LiDAR revenue. The company also appointed Robert Veitch as CEO, signaling a strategic focus on SaaS expansion and diversified geospatial solutions.

MCS Security Services Limited reported a 63% revenue decline following the sale of its Security Business, yet improved its net loss and underlying EBITDA in FY25. The Traffic Business showed promising growth, while the company weighs capital management and potential divestments.

SOCO Corporation Ltd reported a 3.6% revenue increase to $21.29 million for FY25, reversing prior losses with a modest net profit after tax. Operational improvements and strategic hires underpin the company’s renewed momentum.

HighCom Limited reports a sharp 90% reduction in net loss for FY25, turning EBITDA positive and advancing new product development with XTclave technology. Leadership changes and strategic focus set the stage for growth despite cautious US market conditions.

Maggie Beer Holdings Ltd reports a transformative FY25 marked by strategic restructuring, significant cost savings, and a 3.7% sales increase excluding Paris Creek Farms. Despite EBITDA pressures from non-recurring investments, the company is positioning for sustainable profitability and growth in FY26.

Adslot Ltd reported a 34% drop in revenue to $5.77 million for FY25 but significantly reduced its net loss by 65% to $3.7 million, driven by cost cuts and strategic partnerships. The company is focused on growing its Trading Technology segment despite ongoing market challenges.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

4DMedical reports a robust 56% revenue increase in FY2025, driven by SaaS expansion and strategic partnerships, while advancing FDA clearance for its innovative CT – VQ™ lung imaging software.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

DorsaVi Limited reported a 13.9% revenue decline and a 21.7% rise in net loss for FY25, while securing over $3 million in capital to fuel new technology ventures.